Market Overview

GSK and Theravance Announce Completion of the Phase III Programme for Once-Daily LAMA/LABA (UMEC/VI) in COPD

Related GSK
Market Mixed Amid Plan To Spend $300 Million On Ebola Vaccines
#PreMarket Primer: Thursday, December 4: Beige Book Paints Positive Picture Of U.S. Economy
Action in Ebola-Related Stocks (Fox Business)

GlaxoSmithKline plc (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the completion of the phase III programme of an investigational LAMA/LABA involving approximately 6,000 patients with chronic obstructive pulmonary disease.

See full press release

Posted-In: News

 

Related Articles (THRX + GSK)

Around the Web, We're Loving...

Get Benzinga's Newsletters